Clinical Trials on Well-differentiated Non-functional NET of Pancreatic Origin in Belgium

Total 11 results

  • Novartis Pharmaceuticals
    Completed
    Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
    Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
    United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
  • Novartis Pharmaceuticals
    Completed
    Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)
    Neuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung Origin
    United States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
  • Novartis Pharmaceuticals
    Completed
    Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)
    Advanced Neuroendocrine Tumors of Pancreatic Origin
    Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
  • Bristol-Myers Squibb
    Completed
    Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
    Soft Tissue Sarcoma | Transitional Cell Carcinoma | Advanced Non-small Cell Lung Cancer | Gastric/Esophageal Adenocarcinoma | Pancreatic Cancer Including Ampulla of Vater
    United States, Argentina, Germany, Belgium, Canada, Poland, Netherlands, United Kingdom, France
  • EMD Serono Research & Development Institute, Inc.
    Merck KGaA, Darmstadt, Germany
    Active, not recruiting
    Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV
    Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
  • Universitair Ziekenhuis Brussel
    Kom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie...
    Recruiting
    Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients (VUBAR)
    Gastric Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer | Locally Advanced Breast Cancer | Cancer of Pancreas | Uterine Cancer | Salivary Gland Cancer | Metastatic Breast Carcinoma | Solid Tumor With Intermediate...
    Belgium
  • Incyte Corporation
    Completed
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
    Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...
    United States, Spain, France, United Kingdom, Italy, Belgium
  • ADC Therapeutics S.A.
    Terminated
    Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
    Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content | Head and Neck...
    United States, Belgium, United Kingdom
  • Salubris Biotherapeutics Inc
    Recruiting
    Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
    Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions
    Belgium, Spain
  • Actuate Therapeutics Inc.
    Active, not recruiting
    9-ING-41 in Patients With Advanced Cancers
    Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions
    United States, Belgium, Canada, Spain, France, Netherlands, Portugal
  • Centre Hospitalier Universitaire de Liege
    Sanofi; Takeda; University of Liege; Orchard Therapeutics; Centre Hospitalier Régional... and other collaborators
    Recruiting
    Baby Detect : Genomic Newborn Screening
    Congenital Adrenal Hyperplasia | Hemophilia A | Hemophilia B | Mucopolysaccharidosis I | Mucopolysaccharidosis II | Cystic Fibrosis | Alpha 1-Antitrypsin Deficiency | Sickle Cell Disease | Fanconi Anemia | Chronic Granulomatous Disease | Wilson Disease | Severe Congenital Neutropenia | Ornithine Transcarbamylase... and other conditions
    Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe